An application made for this job — a tailored resume and cover letter that speak straight to the posting.
MannKind Corporation, Burlington, MA, is seeking an Accounting Manager, SEC Reporting to lead external financial reporting activities and the monthly/quarterly close cycle. You will prepare SEC filings, footnotes, and supporting schedules while ensuring Sarbanes‑Oxley compliance under the Director of SEC Reporting and Technical Accounting.
The role requires strong analytical skills, attention to detail, and a track record in timely public-company reporting.
Accounting Manager, SEC Reporting
Burlington, MA
Job Id:112989
# of Openings:1
MannKind Corporationis a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions. Focused on cardiometabolic and orphan lung diseases, we develop and commercialize treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. With deep expertise in drug-device combinations, MannKind aims to deliver therapies designed to fit seamlessly into daily life.
Our employees are our greatest asset. We foster a close-knit, collaborative culture where every team member plays a vital role in our mission. We champion a rich blend of backgrounds, perspectives, and working styles as we work together to improve health outcomes and change lives.
The Accounting Manager, SEC Reporting supports the preparation and coordination of the Company’s external financial reporting activities, as well as the monthly and quarterly close process. This role will assist in the preparation of SEC financial filings, consolidated financial statements and footnotes, and financial information supporting quarterly earnings, participate in the month end close process including preparing journal entries and account reconciliations, and helping to maintain the Company’s Sarbanes‑Oxley compliance program. The ideal candidate has strong analytical skills, attention to detail, and a track record of accurate, timely reporting in a fast-paced, publicly traded environment. This position reports to the Director, SEC Reporting and Technical Accounting.
With the spread of the coronavirus, many individuals are concerned about access to their medication supply. At this time, MannKind does not anticipate that the supply of its inhalable insulin Afrezza ® (insulin human) Inhalation Powder will be affected by the coronavirus.
We will continue to closely monitor our supply chain for potential impact to the supply of Afrezza. MannKind sources critical raw materials from suppliers in the United States and Europe and we remain in close communication with key suppliers to assure a reliable supply of insulin.
Our US manufacturing facility is fully operational and we are taking a number of steps to prevent any impact to our supplies. Afrezza is still readily available in U.S. pharmacies, and if needed, pharmacies can order additional supplies from wholesalers with expected delivery within 1-2 days. As the global situation evolves, we will continue to take the necessary steps to safeguard the reliable supply of Afrezza.